Search Results - "Ferreyra, Milagros"

Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial by Lafaurie, Matthieu, Chevret, Sylvie, Fontaine, Jean-Paul, Mongiat-Artus, Pierre, de Lastours, Victoire, Escaut, Lélia, Jaureguiberry, Stéphane, Bernard, Louis, Bruyere, Franck, Gatey, Caroline, Abgrall, Sophie, Ferreyra, Milagros, Aumaitre, Hugues, Aparicio, Caroline, Garrait, Valérie, Meyssonnier, Vanina, Bourgarit-Durand, Anne, Chabrol, Amélie, Piet, Emilie, Talarmin, Jean-Philippe, Morrier, Marine, Canoui, Etienne, Charlier, Caroline, Etienne, Manuel, Pacanowski, Jerome, Grall, Nathalie, Desseaux, Kristell, Empana-Barat, Florence, Madeleine, Isabelle, Bercot, Béatrice, Molina, Jean-Michel, Lefort, Agnès

“…Abstract Background The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. Methods To compare 7 days…”
Get full text

Chemsex in HIV pre‐exposure prophylaxis users: Assessment of mood disorders and addictive behavior by Peyriere, Hélène, Jacquet, Jean‐Marc, Peries, Marianne, Tribout, Vincent, Broche, Béatrice, Mauboussin, Jean‐Marc, Makinson, Alain, Perrollaz, Cyril, Ferreyra, Milagros, Rouanet, Isabelle, Montoya‐Ferrer, Ana, El‐Majjaoui, Said, Corriol‐Bonifas, Florence, Fraisse, Thibaut, Grau, Fanny, Laureillard, Didier, Nagot, Nicolas, Reynes, Jacques, Donnadieu‐Rigole, Hélène

“…The assessment of mood disorders and addiction linked to the practice of chemsex is of interest given the psychoactive substances used. The aim of this study…”
Get full text

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression by Supervie, V, Assoumou, L, Breban, R, Lert, F, Costagliola, D, Pialoux, G, Landman, R, Girard, P M, Slama, L

“…Individuals presenting for care with severe immunosuppression typically have high plasma HIV viral load (pVL) and may transmit HIV before and after initiation…”
Get full text

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial) by Slama, Laurence, Landman, Roland, Assoumou, Lambert, Benalycherif, Aida, Samri, Assia, Joly, Véronique, Pialoux, Gilles, Valin, Nadia, Cabié, André, Duvivier, Claudine, Lambert-Niclot, Sidonie, Marcelin, Anne-Geneviève, Peytavin, Gilles, Costagliola, Dominique, Girard, Pierre-Marie

“…Boosted PIs are commonly prescribed in patients presenting with advanced HIV infection. We assessed the efficacy and tolerability of once-daily…”
Get full text